The short answer
Aleniglipron is a once-daily oral non-peptide GLP-1 receptor agonist developed by Structure Therapeutics. Its Phase 2b ACCESS trial, published in Nature Medicine on 10 August 2026, reported 12.1% mean weight reduction at 36 weeks on 120 mg. The separate ACCESS II trial reported 15.3% absolute reduction at 44 weeks on 180 mg.
Key facts
- Class
- Oral non-peptide GLP-1 receptor agonist
- Developer
- Structure Therapeutics
- Administration
- Once daily, oral
- ACCESS (Phase 2b)
- 230 adults, 36 weeks, 38 US centres
- ACCESS 120 mg result
- −12.1% absolute vs −0.5% placebo
- ACCESS II
- 85 adults, 44 weeks
- ACCESS II 180 mg
- −15.3% absolute, −16.3% placebo-adjusted
- Status
- Phase 2 complete; not authorised anywhere
Why it matters that this is the second one
Orforglipron established that a small molecule could activate the GLP-1 receptor well enough to be a licensed medicine. Aleniglipron is the compound that questions the assumption which followed: that the oral route necessarily costs you effect size. Orforglipron reported 11.2% at 72 weeks on its highest dose. Aleniglipron's ACCESS II reported 15.3% absolute at 44 weeks on 180 mg, in a shorter trial, with the reduction curve still descending at the end.
The two trials, and why they report different numbers
ACCESS is the larger Phase 2b: 230 adults across 38 US medical centres over 36 weeks, published in Nature Medicine on 10 August 2026. Its 120 mg arm reported 12.1% absolute reduction against 0.5% on placebo. ACCESS II is a smaller, longer study (85 adults over 44 weeks) testing 120 mg, 180 mg and 240 mg. Both are correct; they are different trials with different sizes, durations and dose ranges, and coverage routinely quotes one figure without saying which trial produced it.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
A case where placebo-adjusted exceeds absolute
ACCESS II reported 15.3% absolute and 16.3% placebo-adjusted for the 180 mg arm. Placebo-adjusted is the larger of the two, which surprises people who assume adjustment always shrinks a number. The reason is that the placebo arm gained 1.1%, so subtracting it adds to the difference. Compare ACCESS, where placebo lost 0.5% and adjustment would reduce the figure. Whether placebo-adjusted is bigger or smaller than absolute depends entirely on which direction the placebo arm moved.
The dose-response is not monotonic
ACCESS II reported 13.6% at 120 mg, 15.3% at 180 mg and 15.0% at 240 mg on the absolute measure. The highest dose did not produce the largest reduction. With 85 participants split across four arms this is well within the noise a small trial produces, but it is the kind of detail that matters for Phase 3 dose selection and it is not what a clean dose-response curve looks like.
Tolerability and the safety database
Adverse events were primarily gastrointestinal, with nausea and vomiting most common during titration (the class pattern). Discontinuation due to adverse events was reported at 3.7% across active arms at 120 mg or higher between weeks 28 and 44. Across a database of more than 625 participants, Structure Therapeutics reported no drug-induced liver injury, no persistent liver-enzyme elevations and no QTc prolongation.
What is still unknown
These are Phase 2 results, and ACCESS II in particular is small. No Phase 3 data exist, the compound holds no authorisation anywhere, and the absence of a plateau at 44 weeks means the eventual effect size is unknown rather than merely unreported. An open-label extension reported 16.2% at 56 weeks on 120 mg, which is consistent with the curve continuing.
Quick reference
| Trial | n | Duration | Dose | Absolute | Placebo-adjusted |
|---|---|---|---|---|---|
| ACCESS | 230 | 36 wks | 120 mg | −12.1% | - |
| ACCESS II | 85 | 44 wks | 120 mg | −13.6% | −14.7% |
| ACCESS II | 85 | 44 wks | 180 mg | −15.3% | −16.3% |
| ACCESS II | 85 | 44 wks | 240 mg | −15.0% | −16.0% |
| ACCESS OLE | - | 56 wks | 120 mg | −16.2% | - |
Frequently asked questions
Is aleniglipron better than orforglipron?
Its Phase 2 figures are higher, but the comparison is indirect (different trials, durations and populations), and orforglipron has Phase 3 data and an approval while aleniglipron has neither.
Why do sources quote 12.1% and others 16.3%?
Two different trials. 12.1% is ACCESS at 36 weeks on 120 mg, absolute. 16.3% is ACCESS II at 44 weeks on 180 mg, placebo-adjusted.
Is aleniglipron available anywhere?
No. It has completed Phase 2 and holds no marketing authorisation in any jurisdiction.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Semaglutide? Structure, Mechanism and EvidenceSemaglutide is a GLP-1 analogue with 94% homology to native GLP-1. Its structure, the C18 diacid that gives it a weekly half-life, and the SELECT outcome data.
- What Is Tirzepatide? The First Dual Incretin AgonistTirzepatide is a dual GIP and GLP-1 receptor agonist built on a GIP backbone. SURMOUNT-1 reported up to 22.5% weight reduction over 72 weeks.
- Semaglutide vs Tirzepatide: What the Direct Comparison ShowedSURMOUNT-5 randomised 751 adults to tirzepatide or semaglutide for 72 weeks: 20.2% against 13.7% mean reduction. The full comparison, including tolerability.
- What Is the Incretin Effect?Oral glucose produces far more insulin than the same glucose given intravenously. That gap is the incretin effect, and this whole drug class exploits it.
- DPP-4: Why Native Incretins Last Two MinutesDPP-4 removes two residues from GLP-1 and inactivates it within minutes. How Aib8 substitution and albumin binding defeat it, and why small molecules ignore it.